Neoplasms

Symptoms and General Pathology

All Conditions

Rare Diseases

Neoplasm Metastasis

Neuroendocrine Tumors

Neoplastic Processes

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Hematinics

All Drugs and Chemicals

Liver Extracts

two cycles of 177Lutetium radioreceptor therapy within two month

177Lutetium

about 9 month after finishing the receptor therapy liver transplantation takes place

Liver transplantation

Christine Wurst, Dr. med.

Utz Settmacher, Prof. Dr. med

Dieter Hörsch, PD Dr. med.

R. P. Baum, Prof.Dr.med.

Dieter Hoersch, Prof. Dr. med

Christine Wurst, Dr.med.

Utz Settmacher, Prof.Dr. med

Dieter Hörsch, Prof. Dr. med

Utz Settmacher, Prof. Dr. med.

R. B. Baum, Prof.Dr.med.

The purpose of this study is to show the tumor free long term survival of patients with isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio receptor treatment and following liver transplantation.

Matching patient will be treated neo-adjuvant at the hospital with 177 Lutetium peptide receptor radiotherapy in two following courses. After this treatment it will follow the liver transplantation within 9 month as postmortal or living donor liver transplantation.

Under certain conditions concerning the evaluation examinations patients can be included in the study.

Most important factors are no evidence of disease outside the liver, removed primary tumor, patients between 18 and 60 years, no curative surgical resection of the liver metastasis possible.

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors

University of Jena

Dr. med. Christine Wurst

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	NCT01201096	Liver Metastasis Neuroendocrine ...	177Lutetium Liver transplan...	18 Years - 60 Years	University of Jena
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	NCT01201096	Liver Metastasis Neuroendocrine ...	177Lutetium Liver transplan...	18 Years - 60 Years	University of Jena

Spots Global Cancer Trial Database for 177lutetium

Every month we try and update this database with for 177lutetium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 177lutetium

Every month we try and update this database with for 177lutetium cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 177lutetium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.